MétaCan
Menu
Back to cohort
Record W4406468796 · doi:10.1080/14796694.2024.2441107

Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors

2025· article· en· W4406468796 on OpenAlexfundno aff
Kevin J. Harrington, Shigehisa Kitano, Valentina Gambardella, Eileen E. Parkes, Irene Moreno, Guzmán Alonso, Toshihiko Doi, David Berz, Martin Gutierrez, Natalia Fernández, Michael Schmohl, José Barrueco, Patricia LoRusso

Bibliographic record

VenueFuture Oncology · 2025
Typearticle
Languageen
FieldImmunology and Microbiology
Topicinterferon and immune responses
Canadian institutionsnot available
FundersNational Center for Advancing Translational SciencesEli Lilly JapanChugai PharmaceuticalEMD SeronoGenentechSierra OncologySun PharmaRakuten MedicalSTCubeFibroGenAstellas PharmaEisaiRegeneron PharmaceuticalsNateraRelay TherapeuticsSeagenActuate TherapeuticsBeiGeneTaiho PharmaceuticalKyowa Kirin Pharmaceutical DevelopmentPfizerIncyteDaiichi Sankyo EuropeServierGilead SciencesJapan Society for the Promotion of ScienceGlaxoSmithKlineMersana TherapeuticsJapan Agency for Medical Research and DevelopmentRoivant SciencesAmgenAstraZenecaOno PharmaceuticalEli Lilly and CompanyBristol-Myers Squibb
KeywordsMedicineAgonistStingOpen labelOncologyInternal medicineReceptorClinical trial

Abstract

fetched live from OpenAlex

BI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor cells, a combination of BI 1703880 and an anti-programmed cell death protein 1-antibody, such as ezabenlimab, may improve efficacy. This first-in-human phase Ia study (NCT05471856) is evaluating BI 1703880 plus ezabenlimab in patients with advanced solid tumors. The study utilizes an innovative lead-in design; all patients receive BI 1703880 monotherapy in Cycle 1 and combination therapy from Cycle 2. The primary endpoint is dose-limiting toxicities during the maximum tolerated dose evaluation period. Results will inform the future development of BI 1703880 for treatment of metastatic or recurrent malignancies.Clinical Trial number: NCT05471856

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.019

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.003
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.017
GPT teacher head0.363
Teacher spread0.347 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations10
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueFuture OncologySame topicinterferon and immune responsesFrench-language works237,207